1. Introduction {#sec0001}
===============

In the months to years preceding the first psychotic episode, the large majority (i.e., 80--90%) of individuals who are later diagnosed with schizophrenia or a related psychotic disorder experience a prodromal phase characterized by attenuated or transient psychotic symptoms, cognitive and social difficulties, and functional decline (e.g. ([@bib0008]; [@bib0053])). Research efforts in schizophrenia, and psychosis more broadly, focus increasingly on this early phase of psychotic illness development. These studies aim to understand what happens on the neural, cognitive, and functional level as psychosis first develops and, ultimately, to design methods for early intervention.

Intervening early in the disease course, before recurrent or persistent psychosis and functional impairment have developed, may improve clinical outcomes in those at risk for psychosis. Moreover, early intervention may support social and cognitive development of youth prone to psychosis and thereby mitigate the illness' impact on their overall functioning. Early identification of those at risk of developing psychosis is crucial to early intervention. Clinical interviews designed to detect individuals at Clinical High Risk (CHR) for psychosis have shown excellent prognostic accuracies comparable to other tests in preventative medicine ([@bib0021]; [@bib0037]). However, their effectiveness is mediated mainly by their ability to rule out psychosis ([@bib0021]), i.e. to correctly identify those who are *not* at risk rather than differentiating among at-risk individuals in terms of outcome. Given these drawbacks and the limitations of current psychosis treatments, there is a need for improved outcome prediction in high-risk youth.

With the goal of improving outcome prediction for individual CHR subjects, Cannon and others developed a psychosis-risk calculator that uses clinical and neurocognitive data to compute a more precise probability of conversion to psychosis ([@bib0009]). This risk-calculator was designed with data from the American NAPLS-2 cohort, but has been extensively validated with data from independent cohorts from the US ([@bib0012]), UK ([@bib0022]), and China ([@bib0054]). Moreover, studies suggest that further improvements in outcome prediction in high-risk cohorts may be achieved through the use of neurocognitive, neuroimaging, or neurophysiological data, on their own or in addition to clinical data ([@bib0006]; [@bib0009]; [@bib0018]; [@bib0025]; [@bib0029]; [@bib0032]).

The current study aims to assess if fMRI-derived measures of functional connectivity improve outcome prediction in the CHR stage. Long-standing theories posit that psychosis may result from a failure of functional integration in the brain ([@bib0017]; [@bib0020]; [@bib0045]) and fMRI studies have shown abnormalities in task-related activation and functional connectivity of brain regions in individuals at high-risk for psychosis ([@bib0010]; [@bib0038]; [@bib0046]; [@bib0052]). These alterations may, in part, result from a shared underlying abnormality in the brain\'s functional organization ([@bib0014]), which may be evaluated using resting-state fMRI. Indeed, recent findings suggest that measures of functional connectivity and brain network organization derived from resting-state fMRI may be predictive of conversion to psychosis ([@bib0011]; [@bib0016]). We hypothesized that adding measures of functional connectivity and network organization to established clinical and neurocognitive predictors of psychosis may improve outcome prediction in the CHR stage above and beyond clinically-based prediction alone. If functional connectivity measures are found to improve outcome prediction, this would suggest that these measures have potential clinical value and may in the future be used to improve outcome prediction for individual patients.

2. Material and methods {#sec0002}
=======================

2.1. Subjects {#sec0003}
-------------

This study involved a total of 137 Clinical High Risk (CHR) subjects. These subjects were recruited as part of the Shanghai At-Risk for Psychosis (SHARP) program, an international research effort conducted by the Shanghai Mental Health Center (SMHC) in collaboration with the Beth Israel Deaconess Medical Center (BIDMC) and neuroimaging and other data processing laboratories at Brigham and Women\'s Hospital, Massachusetts General Hospital, Harvard University and the Massachusetts Institute of Technology. The study was approved by the Institutional Review Boards of BIDMC and the SHMC. All subjects or their legal guardians provided written informed consent, and minor subjects provided assent.

The current study involves a subgroup of a sample reported on previously ([@bib0016]). The current subgroup comprises only those individuals for whom good-quality imaging data were available, as well as sufficient follow-up data to determine outcome and complete clinical and neurocognitive data as required for the prediction model (details below).

2.2. Clinical evaluation {#sec0004}
------------------------

### 2.2.1. Baseline clinical and cognitive assessments {#sec0005}

Prodromal symptoms were assessed using a validated Chinese version of the Structured Interview for Prodromal Symptoms (SIPS) ([@bib0055]). Neurocognitive functioning was assessed using the MATRICS Consensus Cognitive Battery ([@bib0027]; [@bib0033]), including the Brief Assessment of Cognition in Schizophrenia (BACS) ([@bib0026]) and Hopkins Verbal Learning Test-Revised (HVLT-R) ([@bib0004]). Overall functioning was assessed using the Global Assessment of Functioning (GAF) ([@bib0024]). [Table 1](#tbl0001){ref-type="table"} summarizes demographic, clinical, and cognitive variables.Table 1Clinical and cognitive predictor variables. Group-averaged values of clinical and cognitive variables from the psychosis-risk calculator that entered into the prediction model. SIPS P1 and P2 scores are shown separately here to allow easy interpretation, but a combined value was used in the prediction analysis by rescaling each score down to a maximum of 3 (using 0 for values of 0--2) and adding the scores together. Statistical comparison was performed using analysis of variance for continuous and chi-squared tests for categorical variables.Table 1Good outcome (*N* = 71)Intermediate outcome (*N* = 30)Poor outcome (*N* = 36)StatisticsAge in years, mean (sd)18.6 (4.9)19.3 (5.3)18.6 (4.8)*F~(2134)~* = 0.28\[range\]\[13 to 32\]\[14 to 32\]\[14 to 34\]*p* = .76Positive family history, N (%)6 (9%)3 (10%)5 (14%)*χ^2^* = 0.77*p* = .68GAF change in percentage, mean−29.7 (11.6)−28.3 (6.2)−33.5 (8.5)*F~(2134)~* = 2.71(sd) \[range\]\[−73 to −7\]\[−43 to −20\]\[−47 to −4\]*p* = .07SIPS P1 score, mean (sd)3.3 (1.8)3.2 (1.7)3.7 (1.8)*F~(2134)~* = 0.88\[range\]\[0 to 6\]\[0 to 6\]\[0 to 6\]*p* = .42SIPS P2 score, mean (sd)3.3 (1.7)3.6 (1.7)3.4 (1.7)*F~(2134)~* = 0.19\[range\]\[0 to 6\]\[0 to 6\]\[0 to 6\]*p* = .83HVLT-R score, mean (sd)23.4 (5.7)23.2 (5.4)20.5 (4.7)*F~(2134)~* = 3.6\[range\]\[9 to 33\]\[11 to 33\]\[11 to 29\]*p* = .03BACS-SC score, mean (sd)59.8 (8.7)56.5 (11.1)55.3 (10.0)*F~(2134)~* = 2.9\[range\]\[42 to 75\]\[18 to 75\]\[28 to 73\]*p* = .05

### 2.2.2. Clinical predictor selection {#sec0006}

As clinical predictors, we selected variables included in the psychosis-risk calculator developed for the CHR stage ([@bib0009]) and validated in the SHARP study ([@bib0054]). Following [@bib0054], we used 6 out of the original 8 risk factors in the calculator, including age at baseline, BACS symbol coding raw scores, HVLT-R raw scores, unusual thought content and suspiciousness (quantified as the sum of rescaled SIPS items P1 and P2), change in global functioning (measured as the change in current GAF relative to the preceding year), and having a first-degree family member with psychosis (yes/no). For details on clinical predictors and validation in our sample see [@bib0054].

2.3. Neuroimaging {#sec0007}
-----------------

### 2.3.1. Image acquisition {#sec0008}

Magnetic Resonance Imaging (MRI) scans were acquired on a 3T Siemens MR B17 (Verio) system, 32-channel head coil at the SMHC and included a resting-state functional MRI (rs-fMRI) scan (149 functional volumes; TR = 2500 ms, TE = 30 ms, FA = 90°, FOV = 224 mm, voxel size 3.5 × 3.5 × 3.5 mm^3^, 37 contiguous axial slices, duration 6′19″) and an anatomical T1-weighted MRI scan (MP-RAGE; TR = 2300 ms, TE = 2.96 ms, FA = 9°, FOV = 256 mm, voxel size 1 × 1 × 1 mm^3^, 192 contiguous sagittal slices, duration 9′14″).

### 2.3.2. Image preprocessing {#sec0009}

Image preprocessing was performed using Conn (v17d) software ([@bib0050]) and included segmentation of gray and white matter tissue, realignment, slice-timing correction, normalization to Montreal Neurological Institute (MNI) space, and smoothing (6 mm FWHM Gaussian filter). Potential spurious correlations in rs-fMRI time-series were assessed using the Artifact Detection Tool (ART; <http://www.nitrc.org/projects/artifact_detect>). Outliers were defined as volumes showing head displacement in the x, y, or z direction greater than 1 mm relative to the previous frame or a mean global intensity greater than 3 standard deviations from the mean intensity for the entire rs-fMRI scan. These outlier scans were removed from the data through linear regression. Time-series were corrected for motion (captured by 3 rotational, 3 translational, and 1 composite motion parameter), artefactual covariates, and signals within white matter (i.e., 3 principle component analysis (PCA) parameters) and cerebrospinal fluid (3 PCA parameters) masks through linear regression. Resulting time-series were band-pass filtered (0.008 Hz--0.09 Hz).

### 2.3.3. Imaging predictor selection {#sec0010}

From our previous study on functional connectome organization in CHR ([@bib0016]), we selected Rand similarity coefficients (*S*~R~) for each subject in the current study. Here, *S*~R~ values (between 0 and 1) reflect how typical or atypical the modular organization of a subject\'s connectome organization is relative to an average healthy network, with lower values reflecting a more atypical modular organization. For the current study, the *S*~R~ measure obtained using the Harvard-Oxford atlas included in the default Conn processing pipeline was used (for details see [@bib0016]). In addition to this measure of overall connectome organization, we included measures of functional connectivity (i.e., average Fisher-transformed correlation coefficients) within and between 8 established rs-networks, including default-mode (DMN), salience (SAL), language (LAN), dorsal attention (DA), fronto-parietal (FP), sensorimotor (SM), visual (VIS), and cerebellar (CER) networks. These 8 rs-networks are part of Conn\'s default processing pipeline, as obtained from ICA analysis of 497 subjects from the Human Connectome Project (<https://www.nitrc.org/projects/conn/>). Figure S1 illustrates all included connectome and connectivity measures per group (supplementary materials).

2.4. Outcome assessment {#sec0011}
-----------------------

Subjects were reassessed at one-year follow-up. As the CHR stage has a large heterogeneity in clinical outcome ranging from psychotic conversion to symptom remission ([@bib0008]), we differentiated multiple outcome levels: (1) good outcome or symptom remission, i.e. no longer meeting CHR criteria at follow-up (*N* = 71); (2) intermediate outcome, i.e. still meeting CHR criteria at follow-up (*N* = 30), and (3) poor outcome (*N* = 36), including CHR converters and 'treatment-refractory' CHR individuals, the latter being characterized by worsened symptoms despite antipsychotic treatment but without meeting formal criteria for psychosis.

2.5. Prediction analysis {#sec0012}
------------------------

### 2.5.1. Logistic regression analysis and leave-one-out cross-validation {#sec0013}

The multinomial logistic regression analysis was performed in three steps. First, the logistic regression model was run using only clinical predictors. Second, an imaging-only prediction model that included measures of connectome organization and within/between-network functional connectivity was assessed. Third, the clinical and fMRI measures were combined in one prediction model. Prior to the logistic regression analysis, a PCA analysis was performed to reduce the dimensionality of the predictor data (i.e. up to 43 predictor variables in the combined model). As the resulting PCA components are linearly uncorrelated, this step also averted potential collinearity between variables. A component threshold of 13 was chosen to reach a 10:1 subjects-by-predictor ratio ([@bib0023]; [@bib0035]). Next, leave-one-out cross-validation was performed by fitting all participants except one and predicting out-of-sample outcomes. This was done in an iterative fashion for each participant to build cross-validated predictions. The out-of-sample predictions resulting from the cross-validation were used to estimate measures of model performance.

### 2.5.2. Assessing model performance {#sec0014}

Three measures of model performance were assessed. First, positive predictive values (PPV) were computed for each group as the probability that participants with a predicted outcome label indeed had that outcome. A weighted average PPV was computed as a measure of overall model performance, reflecting the average probability across groups that an outcome label predicted by the model was in fact accurate. Note that as we evaluated three outcome categories with varying prevalence, the chance-level average PPV is approximately 37% here. Second, the sensitivity (or true positive rate) was computed as the proportion of each outcome category that was correctly predicted as such. From these, the model *F*~1~-measure (harmonic mean of the positive predictive value and sensitivity, separately for each outcome category) was used to characterize overall model performance. This measure was compared to expected chance levels using a permutation test with 1000 sampled permutations in order to evaluate the statistical significance of the model\'s prediction. In addition, to perform a statistical comparison of the three models in terms of performance, a resampling with replacement analysis was used to compute the expected distribution of accuracy values for each model. These were compared across models yielding p-values reflecting the difference in prediction performance for each pairwise comparison.

### 2.5.3. Identifying predictor variables driving outcome prediction {#sec0015}

A secondary analysis was performed to explore which variables added most predictive information to the combined model. To this end, prediction coefficients were computed for each predictor variable by multiplying the regressor coefficients of the PCA components with the corresponding component loadings. The directionality of these coefficients is such that positive values indicate that increases in the predictor variable predict better outcome (i.e. a relative increase in the likelihood of symptom remission) and negative values imply that increases in the predictor variable predict worse outcome (i.e. an increased likelihood of poor outcome including conversion to psychosis). Associated standard error and p-values were computed to identify predictors with high influence (details in supplementary materials). Note that this is not a proper confirmatory test, but rather a way to compare the relative influence of predictors and highlight those with the greatest influence.

### 2.5.4. Validation analyses {#sec0016}

As the PCA component threshold of 13 components (chosen to limit the subjects-by-predictor ratio to 10:1) is arbitrary, we performed a validation analysis in which the combined prediction model was rerun for a range of PCA component thresholds from 10 to 15 components.

Motion parameters (i.e., composite motion parameter and the number of removed outlier scans) were compared between groups, and included in the combined prediction model to assess the possible influence of head motion on our results.

Moreover, to test for possible systematic group-differences in other factors that may contribute to differential patterns of functional connectivity, outcome groups were compared on their scores on SIPS item D4 (trouble with focus and attention) and G4 (tolerance to normal stress), as measures of attention and anxiety/stress-levels.

3. Results {#sec0017}
==========

[Fig. 1](#fig0001){ref-type="fig"} illustrates the performance of each of the three models in the logistic regression analysis, i.e. clinical-only, imaging-only, and combined model. In addition, the confusion matrix obtained for each prediction model is provided in the supplementary materials.Fig. 1Step-wise performance of prediction models. (A) Weighted average positive predictive value (PPV) across groups for each of the three models as a measure of overall model performance, reflecting the average probability that an outcome label predicted by the model was in fact accurate (relative to 37% chance-level). Note that the clinical-only model includes both clinical and cognitive predictors and that the imaging-only model includes both connectome and connectivity measures. (B) changes in outcome prediction relative to the prevalence of each outcome category in the overall sample, illustrating that outcome prediction improved in a step-wise fashion from the clinical-only to the combined model for good and poor outcome groups, with the steepest improvement in the poor outcome group.Fig 1

3.1. Clinical-only prediction model {#sec0018}
-----------------------------------

Using only clinical and cognitive predictors, the model was unable to predict the three outcome categories to a significant degree (*F*~1~ = 0.32, *F*~1-chance~ = 0.26 ± 0.06, *p* = .154).

3.2. Imaging-only prediction model {#sec0019}
----------------------------------

Using only rs-fMRI derived measures of connectome organization and within/between-network functional connectivity yielded a significant prediction model (*F*~1~ = 0.41, *F*~1-chance~ = 0.29 ± 0.06, *p* = .016). Positive predictive values were 60% for good, 24% for intermediate, and 39% for poor outcome (weighted average PPV of 47%), with sensitivities of 52%, 30%, and 42% respectively. The imaging-only model showed a trend-level improvement in prediction performance relative to the clinical-only model (*p* = .06).

3.3. Combined prediction model {#sec0020}
------------------------------

Combining clinical and imaging measures improved the performance of the prediction model (*F*~1~ = 0.46, *F*~1-chance~ = 0.29 ± 0.06, *p* \< .001). The combined model yielded positive predictive values of 63% for good, 24% for intermediate, and 51% for poor outcome, with sensitivities of 52%, 30%, and 58% respectively. The weighted average PPV was 51%, which is an improvement of 39% relative to chance-level and 32% relative to the clinical-only model. In direct comparison, the combined model significantly outperformed the clinical-only-model (*p* = .02), but was not statistically better than the imaging-only model (*p* = .16).

3.4. Identifying variables driving outcome prediction {#sec0021}
-----------------------------------------------------

Analyzing prediction coefficients for each variable in the combined prediction model ([Fig. 2](#fig0002){ref-type="fig"}) showed that GAF functional decline, verbal learning performance (HVLT-R), and a family history of psychosis were the most influential clinical variables. Greater functional decline and a positive family history predicted worse outcome, while higher verbal learning scores predicted better outcome at one-year follow-up. For fMRI-derived measures, influential predictors included modular connectome organization, DMN and FP within-network connectivity, and between-network connectivity among LAN, DA, CER, SM, and SAL networks. Higher within-network connectivity predicted worse outcome, while higher between-network connectivity and more typical modular connectome organization predicted better outcome. Beta- and p-values for each predictor variable in each model are provided in the supplementary materials.Fig. 2Predictor coefficients for combined prediction model. Plot showing the mean prediction coefficient and associated standard error for each individual predictor variable in the combined model. Positive values indicate that increases in the predictor variable are associated with a relative increase in the likelihood of good outcome, while negative values imply that increases in the predictor variable are associated with a relative increase in the likelihood of poor outcome. Predictors with greatest influence (*p* \< .05) are highlighted in red. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig 2

3.5. Validation analyses {#sec0022}
------------------------

A validation analysis testing the combined model across a range of PCA component thresholds confirmed the main results. Specifically, each threshold yielded a significant level of outcome prediction and the variables identified as the most influential predictors in the model were largely stable across thresholds (supplementary materials, Fig. S2).

There were no significant group-differences in the composite motion parameter (*F*~2,134~ = 0.88, *p* = .416) or the number of removed outlier scans (*F*~2,134~ = 1.19, *p* = .307). Including these measures in the combined prediction model did not change our main results (*F~1~* = 0.46, *p* = .01 and *F~1~* = 0.43, *p* = .01 for motion parameter and number of removed scans respectively).

Assessing other factors that could have contributed to differential patterns of functional brain connectivity did not show significant group-differences in focus/attention problems (*F*~2,134~ = 0.40, *p* = .673) or tolerance to stress (*F*~2,134~ = 0.18, *p* = .836).

4. Discussion {#sec0023}
=============

The results of this study in a large sample of adolescents and young adults at CHR for psychosis indicate that rs-fMRI data contain predictive information that may help to improve outcome prediction in the prodromal stage beyond validated clinical and cognitive predictors of psychosis alone. An imaging-only and combined (clinical/imaging) prediction model were both found to yielde a significant level of outcome prediction, while a clinical-only model was unable to predict good, intermediate, or poor outcome to a significant degree. Relative to the clinical-only model, the combined model showed a 32% improvement in average PPV, reflecting the probability that a predicted outcome label matched the actual outcome. These findings suggest two main points. First, that brain abnormalities reflected by alterations in functional connectivity precede and possibly drive subsequent changes in clinical functioning. And second, that neuroimaging markers of functional connectivity may be useful for improving early identification and clinical decision-making in prodromal psychosis.

In our current study, baseline clinical and cognitive measures alone were unable to predict outcome to a significant degree. The clinical and cognitive predictors were taken from the NAPLS-2 psychosis risk calculator ([@bib0009]) that was previously validated by our group in a larger cohort that included our current sample ([@bib0054]). We note that the sample size of this previous study was approximately 50% larger because our current sample was limited to subjects for whom we had both complete clinical *and* imaging data. Another important distinction between the previous investigation and our current study is that the previous study distinguished CHR individuals who developed psychosis from those who did not convert to psychosis, rather than predicting clinical outcome more broadly as in our current study. As the risk-calculator from which the clinical predictors were taken was developed for predicting psychosis specifically, these predictors may not be equally effective in predicting outcome beyond conversion to psychosis.

Our findings show that fMRI-derived measures of functional connectivity may be useful for improving outcome prediction in prodromal psychosis. A number of previous studies support the hypothesis that changes in functional brain connectivity are predictive of outcome in at-risk individuals. In a study in CHR individuals from the NAPLS-2 study, hyperconnectivity in a cerebello-thalamo-cortical network predicted time to conversion to full psychosis ([@bib0011]). Moreover, a study comparing high-risk subjects who subsequently converted to psychosis to controls and nonconverters found increased midbrain-prefrontal cortex functional connectivity in converters only ([@bib0001]). Another study comparing converters and nonconverters showed that reduced functional connectivity between the bilateral insula was most pronounced in converters ([@bib0049]). Finally, a graph theoretical analysis of functional connectivity data showed reduced topological centrality of the anterior cingulate gyrus in high-risk subjects who later converted to psychosis ([@bib0030]). There is thus some, albeit limited, data to suggest that abnormalities in functional brain organization predate the onset of psychosis, and may be predictive of transition to psychosis in at-risk individuals.

The notion that abnormal functional brain organization precedes and possibly drives the manifestation of full-blow psychosis is further supported by a graph theoretical study by our own group in a larger sample that includes the current CHR sample ([@bib0016]). This study showed that abnormal modular organization of the functional connectome is more common in CHR individuals who subsequently develop psychosis and predictive of shorter time to conversion. Our current findings support these previous results as they show that the predictive effect of the modular connectome measure holds up in cross-validation and extends to outcome more broadly. Combined with validated clinical and cognitive predictors of psychosis, the combined model achieved a weighted average PPV of 51%, which is a 39% improvement relative to chance-level (i.e. with chance-level here being 37% given that we assessed three outcome categories with varying prevalence). Outcome prediction was particularly enhanced for the poor-outcome group, for which the model yielded a positive predictive value of 51%, given a prevalence of poor outcome in the overall sample of just 26%. It is this poor outcome group for whom enhanced outcome prediction is most important, as higher prognostic certainty may allow more targeted early intervention and thereby hopefully improve outcome.

Combined with previously identified clinical and cognitive predictors of outcome in prodromal psychosis, we found several influential measures of within and between-network connectivity in the combined prediction model. First, higher DMN and FP within-network connectivity was associated with a higher likelihood of poor outcome. For the DMN, this finding fits well within the existing literature showing DMN hyperconnectivity in schizophrenia and high-risk individuals ([@bib0002]; [@bib0007]; [@bib0039]; [@bib0042]; [@bib0051]). The association between higher connectivity within the FP network (FPN) and poor outcome is reported less frequently. Hyperconnectivity involving the FPN has been shown in schizophrenia and CHR, but mostly between FPN and other regions including (auditory) SM and DMN ([@bib0007]; [@bib0011]; [@bib0013]; [@bib0041]). Intriguingly, however, a recent study showed that higher cohesiveness of the FPN is predictive of poor response to antipsychotic treatment ([@bib0019]). As our poor-outcome group comprised both CHR converters and treatment-refractory subjects (i.e., showing worsened symptoms despite antipsychotic treatment, without meeting formal criteria for psychosis), we performed a post-hoc analysis to assess group-differences in FPN and DMN connectivity across CHR remitter, symptomatic, treatment-refractory, and converter groups. This analysis showed that while the association between DMN hyperconnectivity and poor outcome is indeed driven by the converter group, the association between FPN hyperconnectivity and poor outcome seems to be driven mainly by the treatment-refractory group, who show significantly higher FPN within-network connectivity than both remitter and symptomatic groups ([Fig. 3](#fig0003){ref-type="fig"}). Our study thus supports previous findings that increased connectivity in the frontoparietal central-executive network is predictive of poor response to antipsychotic treatment ([@bib0019]).Fig. 3Post-hoc group-comparison of DMN and FPN within-network connectivity. Bar chart showing result of post-hoc analysis comparing within-network connectivity for DMN and FP networks across four outcome groups, confirming the hypothesis that the association between DMN hyperconnectivity and poor-outcome was driven particularly by converters, while FPN hyperconnectivity was mainly associated with treatment-refractory status.Fig. 3

In terms of between-network variables, our secondary analysis of predictor coefficients showed that between-network connectivity between the LAN and the SM and DA network, as well as between DA and SAL networks and the CER network were among the most influential predictors in the combined model. Interestingly, whereas higher within-network connectivity was associated with a higher chance of poor outcome, between-network measures showed the opposite association, with higher connectivity predicting a higher likelihood of good outcome. This finding is of interest in light of hypotheses that schizophrenia symptoms may stem from a failure to establish adequate integration between functional brain systems in development ([@bib0015]). Furthermore, studies have suggested that the transition from adolescence to early adulthood, when psychosis tends to develop, is characterized by a fundamental reorganization of large-scale functional brain networks ([@bib0028]; [@bib0047]; [@bib0048]). Abnormalities in the development of precise temporal coordination between distributed brain networks may thus contribute to the emergence of cognitive deficits and psychotic symptoms in schizophrenia ([@bib0048]). In line with these hypotheses, our current findings suggest that higher functional coherence between large-scale brain networks is predictive of better outcome in prodromal psychosis.

There are a number of limitations to our study. First, our clinical-only prediction model failed to reach a significant level of prediction, even though we selected clinical variables aimed specifically at predicting outcome in the prodromal stage. The importance of variable selection in multimodal prediction models in the CHR stage has been stressed in previous literature ([@bib0031]). Specifically, an important concern is that a too limited scope of variables included in the clinical model may overemphasize the additive predictive power of imaging data. As we aimed to predict outcome in a broader sense, including psychotic conversion as well as ongoing subclinical symptoms and symptomatic remission, our clinical-only model may have performed better if it had also included variables associated with resilience to psychosis. However, there is a paucity of research into factors conferring resilience to psychosis. Future studies including resilience factors in addition to risk factors may help improve outcome predictions in at-risk groups. The clinical-only model may have also performed better if we had included a healthy control group, in line with the notion that the effectiveness of clinical predictors of psychosis is mediated primarily by their ability to 'rule out' psychosis ([@bib0021]). However, the purpose of our current study was specifically to differentiate among high-risk individuals in terms of psychosis, rather than identifying those not at risk. Second, rs-fMRI-derived measures of functional connectivity are known to be sensitive to physiological and head motion artifacts ([@bib0036]; [@bib0040]). We dealt with these issues to the best of our ability by using the anatomical CompCor (aCompCor) method to reduce physiological noise ([@bib0003]) and the Artifact Detection Tool (art) to identify motion and artifactual timepoints and mititgate their effects ([@bib0050]), but we cannot rule out the possibility that these confounders influenced our results. Similarly, other factors such as levels of stress, anxiety, and attention/awareness, which are known to influence functional brain patterns ([@bib0005]; [@bib0034]; [@bib0043]; [@bib0044]) may have influenced our results, although we found no significant group-differences in SIPS items measuring tolerance to stress and attention problems. Third, we reiterate that our post-hoc analysis identifying variables that contributed most predictive information to the overall model is not a proper confirmatory test. Our analysis is intended to allow a meaningful comparison of the relative influence of predictor variables and highlight those with high influence, but we note that predictor coefficients of several other clinical and imaging variables were similar in magnitude. Validation in an independent sample is the only proper way to ascertain the relative importance of the predictor variables in our current study to outcome prediction in CHR more generally. Collaborations among CHR consortia are warranted to allow external validation of neuroimaging findings in the high-risk stage. Such future studies would benefit from improved resolution of rs-fMRI acquisition.

In conclusion, the current findings suggest that rs-fMRI-derived measures of connectome organization and functional connectivity, on their own or in addition to clinical predictors of psychosis, improve outcome prediction in the prodromal stage. Outcome prediction was found to be particularly enhanced for poor outcome CHR individuals, which is a promising result as improved prediction of those at the highest risk for poor outcome may contribute to targeted early intervention aimed at improving clinical and functional outcome. Moreover, our findings support the notion that changes in functional connectivity and brain network organization precede and possibly drive subsequent progression of illness in prodromal psychosis.
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